199 related articles for article (PubMed ID: 35357078)
21. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
22. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
23. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
24. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
25. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Elyashiv O; Ledermann J; Parmar G; Farrelly L; Counsell N; Feeney A; El-Khouly F; Macdonald I; Neto A; Arthur-Darkwa E; Burnett E; Jayson GC; Mileshkin L; Gourley C; Nicum S
Int J Gynecol Cancer; 2021 Jan; 31(1):134-138. PubMed ID: 33097567
[TBL] [Abstract][Full Text] [Related]
26. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
[TBL] [Abstract][Full Text] [Related]
27. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
28. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
29. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract][Full Text] [Related]
30. Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Bourien H; Lefevre LB; Mouret-Reynier MA; Asselain B; Lucas B; Gavoille C; Cornila C; Gavoille L; Colomba E; Patsouris A; Fabbro M; Chakiba C; Toussaint P; Simon H; Berton D; Garbay D; Tixidre CG; Coeffic D; Morvan A; Collard O; DE LA Motte Rouge T
Anticancer Res; 2023 Feb; 43(2):653-662. PubMed ID: 36697069
[TBL] [Abstract][Full Text] [Related]
31. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Francis KE; Kim SI; Friedlander M; Gebski V; Ray-Coquard I; Clamp A; Penson RT; Oza A; Perri T; Huzarski T; Martin-Lorente C; Cecere SC; Colombo N; Ataseven B; Fujiwara K; Sonke G; Vergote I; Pujade-Lauraine E; Kim JW; Lee CK
Ann Oncol; 2022 Jun; 33(6):593-601. PubMed ID: 35219776
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Yoshihama T; Kuroda Y; Chiyoda T; Takahashi M; Yoshimura T; Saotome K; Nanki Y; Sakai K; Kobayashi Y; Yamagami W; Aoki D
Int J Clin Oncol; 2022 Oct; 27(10):1644-1650. PubMed ID: 35835930
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J
Br J Cancer; 2018 Oct; 119(9):1075-1085. PubMed ID: 30353045
[TBL] [Abstract][Full Text] [Related]
34. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract][Full Text] [Related]
35. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
36. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y; Kim JW; Penson RT; O'Malley DM; Parkinson C; Roxburgh P; Plummer R; Im SA; Imbimbo M; Ferguson M; Rosengarten O; Steeghs N; Kim MH; Gal-Yam E; Tsoref D; Kim JH; You B; De Jonge M; Lalisang R; Gort E; Bastian S; Meyer K; Feeney L; Baker N; Ah-See ML; Domchek SM; Banerjee S;
Clin Cancer Res; 2024 Jan; 30(1):50-62. PubMed ID: 37939124
[TBL] [Abstract][Full Text] [Related]
37. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See ML; Moore KN;
J Clin Oncol; 2023 Jan; 41(3):609-617. PubMed ID: 36082969
[TBL] [Abstract][Full Text] [Related]
38. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
Cao Y; Chen H; Huang Y; Hu H
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
[TBL] [Abstract][Full Text] [Related]
39. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK
Eur J Cancer; 2021 Sep; 154():190-200. PubMed ID: 34293664
[TBL] [Abstract][Full Text] [Related]
40. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
